BioSpace News Archive

ZipLine Medical, Inc. announced presentation of positive results from a randomized, prospective clinical study conducted at the Karolinska University Hospital in Stockholm, Sweden demonstrating both clinical and economic benefits of the Zip® Surgical Skin Closure device when used in an emergency medicine setting for lacerations.

Inovio Pharmaceuticals, Inc. (NASDAQ: INO) announced today that its Ebola vaccine, INO-4201, was safe, tolerable, and generated strong T cell and antibody responses.

The Migrant Rights Network, a new cross-Canada alliance to demand pro-migrant, anti-racist laws and policies, including permanent residence status for all, is launching today, the International Day for the Elimination of Racism (March 21)

The Supreme Cannabis Company, Inc. (“Supreme Cannabis” or the “Company”) (TSX: FIRE) (OTCQX: SPRWF) (FRA: 53S1) today announced that its wholly-owned subsidiary, 7ACRES, has obtained Health Canada approval for six additional flowering rooms totaling 60,000 sqft of additional production space at its facility in Kincardine, Ontario.

Sonendo, a market-leading dental technology company, and developer of the GentleWave® System announced today three new additions to its leadership team in support of its rapid commercial growth.

According to the Missouri Mesothelioma Victims Center, “Depending how or where an electrician or plumber with mesothelioma was exposed to asbestos, the potential claim could be worth a million dollars or more.

GenePOC Inc., member of the Debiopharm Group, announces its third test to be cleared by the FDA, the GenePOC Strep A assay, to be used with the revogene™ device.

Crescita Therapeutics Inc. (TSX: CTX) (Crescita or the Company), a commercial dermatology company with a portfolio of non-prescription skincare and prescription drug products for the treatment and care of skin conditions, diseases and their symptoms, today reported its financial results for the fourth quarter and fiscal year ended December 31, 2018.

Candel Therapeutics (a.k.a. Advantagene, Inc.) announced today the treatment of the first high grade glioma patients in a study of its Gene Mediated Cytotoxic Immunotherapy (GMCI™; aglatimagene besadenovec plus prodrug) in combination with the checkpoint inhibitor nivolumab and standard of care (SOC) surgery, radiation and temozolomide.

The US Navy Veterans Mesothelioma Advocate is appealing to a Navy Veteran who has just been diagnosed with mesothelioma or their immediate family to call them anytime at 800714-0303 for on the spot access to famed attorney Erik Karst and his amazing colleagues at the law firm of Karst von Oiste.